Generic
Omeprazole
Brand Name
Prilosec
Import ID
169
Omeprazole
| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Rilpivirine (IM) Omeprazole | Green: Administer standard doses | Administer standard doses | |||||
| Darunavir Omeprazole 915 | Green: Administer standard doses | Administer standard doses | No significant change |
20 mg once daily | Not reported |
||
| Darunavir Omeprazole 869 | Yellow: Adjust dosing | Adjust dosing to avoid decreased levels of omeprazole | Potential decreased omeprazole efficacy |
No significant change |
40 mg x 1 | Cmax decrease 34%, AUC decrease 42% |
Consider using alternative agents. If coadministering, monitor for omeprazole efficacy. If no symptomatic relief, increase dose to no more than 40 mg once daily |
| Atazanavir Omeprazole 784 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 94%, Cmax decreased 96%, Cmin decreased 95% |
40 mg daily x 5 d | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 783 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 76%, Cmax decreased 72%, Cmin decreased 78% |
40 mg daily x 10 d | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 782 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 70%, Cmax decreased 66%, Cmin decreased 76% |
40 mg daily x 10 d | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 781 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 61%, Cmax decreased 56%, Cmin decreased 66% |
40 mg daily x 10 d | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 780 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 42%, Cmax decreased 39%, Cmin decreased 46% |
20 mg daily on d 17-23 | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 779 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Potential loss of antiretroviral efficacy |
Atazanavir AUC decreased 30%, Cmin decreased 31%, Cmax decreased 31% |
20 mg daily on d 17-23 | Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
|
| Atazanavir Omeprazole 778 | Yellow: Adjust dosing | Adjust dosing to avoid reduced levels of atazanavir | Increased omeprazole effects |
Not reported |
40 mg x 1 on d 7 and 20 | Omeprazole AUC increased 45%, Cmax increased 24% |
Do not coadminister PPIs with unboosted atazanavir. PPIs may be administered 12 hours before atazanavir when boosted with ritonavir or cobicistat, in treatment naive patients. Doses should not exceed the equivalent of omeprazole 20 mg daily. PPIs are not recommended for treatment experienced patients. |
| Rilpivirine Omeprazole 663 | Red: Avoid combination | Do not coadminister: Reduced levels of rilpivirine | Decreased rilpivirine effects |
Rilpivirine AUC decreased 40%; Cmin decreased 33%; Cmax decreased 40% |
20 mg daily | No significant change |
Contraindicated. Use alternative agents. |
| Etravirine Omeprazole 535 | Green: Administer standard doses | Administer standard doses | Etravirine AUC increased 41% |
40 mg daily x 11 days | |||
| Doravirine Omeprazole 344 | Green: Administer standard doses | Administer standard doses | Potential decrease in antiretroviral efficacy. |
AUC decreased 17%; Cmin decreased 16% |
|||
| Raltegravir Omeprazole 297 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 39%; Cmax increased 50%; Cmin increased 24% |
20 mg daily | Not reported |
||
| Raltegravir Omeprazole 296 | Green: Administer standard doses | Administer standard doses | Raltegravir AUC increased 212%; Cmin increased 46%; Cmax increased 315% |
20 mg daily x 4 days | |||
| Elvitegravir Omeprazole 133 | Green: Administer standard doses | Administer standard doses | If omeprazole given 2 hours before EVG, Cmax increased 16%, AUC increased 10%, Cmin increased 13%. If given 12h after, no significant change. |
20 mg given 2 hours before or 12 hours after elvitegravir | Not reported |
||
| Dolutegravir Omeprazole 108 | Green: Administer standard doses | Administer standard doses | No significant change |
40 mg once daily | Not studied |
